GLP-1 receptor agonist injections for treating type 2 diabetes mellitus

Published on 19 Dec 2022
Last Updated on 19 Dec 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Dulaglutide 0.75 mg and 1.5 mg solution for injection in pre-filled pen for treating type 2 diabetes mellitus:

  • as a triple therapy in combination with two oral anti-diabetic drug (OAD) therapies for patients with inadequate glycaemic control despite treatment with optimal doses of dual OAD therapy, or as a dual therapy in combination with one OAD therapy if a dual OAD therapy is contraindicated or not tolerated; and

  • in combination with insulin and metformin, unless metformin is contraindicated or not tolerated.

Funding status

Dulaglutide 0.75 mg and 1.5 mg solution for injection in pre-filled pen is recommended for inclusion on the MOH Medication Assistance Fund (MAF) for the abovementioned indications from 1 February 2023.

MAF assistance does not apply to any formulations or strengths of liraglutide or semaglutide for treating type 2 diabetes mellitus.

GLP-1 receptor agonist injections for treating type 2 diabetes mellitus (19 December 2022) [PDF, 129 KB]

PES Non-insulin injectable drugs for treating type 2 diabetes mellitus (19 December 2022) [PDF, 114 KB]